Zacks Investment Research
27 Nov 2025, 18:01 UTC · 44w ago
Impact · against what's priced in
Ironwood Pharmaceuticals shows strong commercial momentum for Linzess with significant year-over-year growth in both net sales and profit share. While the company faces high concentration risk due to its limited pipeline, the current financial trajectory is positive.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
Ironwood Pharmaceuticals' share of net profits from Linzess sales in the US grew 35% year-over-year to $119.6 million in the third quarter.
More positive than 78% of claims this week
Net sales for Linzess in the United States increased 40% year-over-year to $314.9 million in the third quarter.
Continue reading
5 related stories
Linzess US net sales grew 40% year-over-year to $314.9 million, while Ironwood's share of net profits rose 35% to $119.6 million.
Read from the article alone
No priced-in read yet
The strong 40% growth in Linzess net sales is a positive result for the collaborative arrangement, though likely immaterial to AbbVie's overall valuation.
Read from the article alone
Scored by the NIS engine · methodology.
More positive than 65% of claims this week
Ironwood Pharmaceuticals and Puma Biotechnology both have market capitalizations under $1 billion and are highly dependent on a single marketed product each.
More negative than 70% of claims this week
Which stocks this story touches
More positive than 74% of ticker scores this week
Linzess sales have picked up momentum with a 35% year-over-year increase in the company's share of net profit.
More positive than 64% of ticker scores this week
Reported strong demand for Linzess with net sales up 40% year over year.
Near neutral — 91% of ticker scores this week are stronger
Mentioned as a small biotech with a limited pipeline and dependence on a single product, but no specific financial trend is provided.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
1h ago
−2.9%
Price is moving against the score
$3.75 vs $3.86 close before publication (Nov 26) · not market-adjusted
IRWD chart →+17.2%
Price agrees with the score
$266.79 vs $227.66 close before publication (Nov 26) · not market-adjusted
ABBV chart →
